SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt) Long Term Debt

SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt) posts a long-term debt of $4.5M as of June 2026. That compares with $5.5M in the prior-year period — down 17.7% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt)'s long-term debt was $5.5M. The latest reading is $4.5M — a 17.7% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Long-Term Debt is one piece of SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt)'s financial statement story. At $4.5M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for BCYPU's long-term debt usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt)'s other metric pages and overview cover the third.